RecruitingPhase 3NCT06367283

Metformin Treatment of Patients with Hand Osteoarthritis

Metformin Treatment of Patients with Hand Osteoarthritis: a Randomised, Placebo-controlled Trial


Sponsor

Marius Henriksen

Enrollment

150 participants

Start Date

Jun 3, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

To compare metformin (2 g daily), or maximum tolerated dose, for 16 weeks with placebo as a treatment of hand osteoarthritis symptoms.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Metformin and a drug called Placebo for people with hand osteoarthritis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetformin

Metformin will be initiated at 500 mg once daily with breakfast meal. The dose will be increased with 500 mg every week until 2 g/day is reached, distributed as 1000 mg every morning and evening, together with a meal. If the subject cannot tolerate the maximum dose (2 g/day), the maximal tolerated dose will be given. The treatment period including titration is 16 weeks.

DRUGPlacebo

Participants in the placebo group will receive a placebo tablet identical to the metformin tablet


Locations(1)

The Parker Institute, Bispebjerg and Frederiksberg hospital

Copenhagen, Frederiksberg, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06367283


Related Trials